Inhibitex

company

About

Inhibitex is a clinical-stage biopharmaceutical company dedicated to the development of innovative products that can treat or prevent.

  • 11 - 50

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
$20M
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 1994
Number Of Employee
11 - 50
Operating Status
Active

Inhibitex is a clinical-stage biopharmaceutical company dedicated to the development of innovative products that can treat or prevent serious infections. They are applying our expertise in the development of a portfolio of high-value, differentiated infectious disease therapies, each of which has the potential to significantly improve existing standards of care. Their pipeline addresses major viral and bacterial infections, including herpes zoster (shingles), HCV, and S. aureus infections.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$20M
Inhibitex has raised a total of $20M in funding over 2 rounds. Their latest funding was raised on Feb 11, 2002 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 11, 2002 Series Unknown $20M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Inhibitex is funded by 1 investors. CDP Sofinov are the most recent investors.
Investor Name Lead Investor Funding Round
CDP Sofinov Series Unknown